I'm thinking that management isn't to worried about SP at the moment, if they were we would see some announcements of repeating good news and updates on reporting dates extra . Now why would they take this pathway? Market impact.
Imagine the response.
FDA conditional approval, expanded deal with our Japanese partner to sell too the world. Through in some results from CHF and a new P3 for inflammation with global support .
Perfect for a good out come in regards to lifting our cash supply.
I'm thinking that management isn't to worried about SP at the...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.045(3.33%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.42 | $1.33 | $3.802M | 2.753M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23940 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 22571 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |